Taysha Gene Therapies, Inc.
TSHATaysha Gene Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.8 million, up 17.3% from fiscal 2024.
- Revenue
- +206.8%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- −6.92%
Quarter to September 2026, against a year earlier
After hours trading: 4.00, down 0.25%, last trade Tue 4:01pm Eastern.
Follow TSHA
Alert me
Taysha Gene Therapies, Inc. (TSHA) Return on invested capital
Taysha Gene Therapies, Inc.'s return on invested capital over the twelve months to 30 September 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −54,849.5% (fiscal 2020) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 54,849.49 |
| FY2020 | −54,849.5% | (54,849.49) |
| FY2019 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVAX Novavax, Inc. compare | 0.00% |
| OCUL Ocular Therapeutix, Inc. compare | 0.00% |
| MLYS Mineralys Therapeutics, Inc. compare | 0.00% |
| GENB Generate Biomedicines, Inc. compare | 0.00% |
| GHRS GH Research PLC compare | 0.00% |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | 0.00% |
| TSHA Taysha Gene Therapies, Inc. | 0.00% |
| AVLN Avalyn Pharma Inc. compare | −127.6% |
| ABSI Absci Corporation compare | −182.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)